ABG Analyst expects significant costs increase at Coloplast

ABG Sundal Collier has lowered its recommendation for Coloplast from "hold" to "sell" as it anticipates that the medtech company's costs will increase considerably in the future.

BY MARKETWIRE OG CHRISTOPHER DUE KARLSSON, TRANSLATED BY DANIEL PEDERSEN

Published: 06.10.21 at 10:14

Coloplast has had its recommendation lowered to "sell" from "hold" by the investment bank ABG Sundal Collier.

The share price target has also been lowered to DKK 900 (USD 140) from DKK 1141 (USD 177).

Already a subscriber? Log in.

Read the whole article

Get 14 days free access.
No credit card required.

Access all locked articles
Receive our daily newsletters
Access our app

Start a free company trial today

"Real world" patient data documents the long-term effects of ALK vaccines

Data from ALK's React study, which is a retrospective real-world evidence study including more than 92,000 patients with respiratory allergies, have just been published in the journal The Lancet Regional Health – Europe. | Foto: ALK / PR

In the largest study ever of its kind, patient data from the "real world" documents the long-term effects of up to nine years of ALK vaccines. Up until now, it has not been possible to demonstrate these in ordinary clinical studies where the follow-up period is shorter, and the new knowledge could be a turning point in ALK's dialog about prices and subsidies with authorities and payers.